Citigroup’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Citigroup’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-187,500	Closed	-$17.8M	–	6695
2020 Q4	$17.8M	Hold	187,500	–	–	0.01%	1114
2020 Q3	$13.5M	Hold	187,500	–	–	0.01%	1154
2020 Q2	$13.2M	Hold	187,500	–	–	0.01%	1122
2020 Q1	$9.5M	Hold	187,500	–	–	0.01%	1198
2019 Q4	$11.7M	Hold	187,500	–	–	0.01%	1357
2019 Q3	$9.38M	Buy	+187,500	New	+$10.6M	0.01%	1450

Other funds holding GNOM

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Citigroup's GNOM Position: Q1 2021 in Review

Citigroup sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q1 2021, closing a stake of 187,500 shares — an estimated $17.8M sold.

Citigroup first reported a position in GNOM in Q3 2019 and held it in 6 quarters. The position peaked at $17.8M in Q4 2020. 38 funds tracked by Wall St. Rank hold GNOM as of Q1 2021.

Citigroup reported no remaining Global X Genomics & Biotechnology ETF position as of Q1 2021 after selling out during the quarter.
Citigroup sold 187,500 Global X Genomics & Biotechnology ETF shares in Q1 2021, an estimated $17.8M.
Citigroup first reported a position in Global X Genomics & Biotechnology ETF in Q3 2019 and held it in 6 quarters.
Citigroup's Global X Genomics & Biotechnology ETF position peaked at $17.8M in Q4 2020.
38 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2021.

Based on Citigroup's 13F filing for Q1 2021, filed 13 May 2021.